Thread Content
On the long journey from the laboratory to patients, there is a type of intangible core asset that determines whether a new drug can be developed, produced on a large scale, and made available to everyone – and that is pharmaceutical intermediates. From target discovery to clinical application, from pilot production on a kilogram scale to commercial production at a ten-thousand-ton level, behind every innovative drug, there is the essential support of intermediate technologies, cost control, and supply chain management. It is not the drug itself, but it serves as the cornerstone and lifeblood of the innovative pharmaceutical industry; on its own, it has become an important foundation for innovative drugs in China. I. Fundamental positioning: Without intermediates, there can be no innovative drugs. The essence of innovative drugs lies in the precise construction of complex molecules, and the synthesis of active pharmaceutical ingredients (APIs) often requires 8–15 chemical reactions, with each step relying on high-purity intermediates to assemble the molecular structure. It is the “building block” of drug molecules: cutting-edge therapies such as targeted drugs, ADCs, PROTACs, and small nucleic acids all rely on special intermediates as their backbone ； It is the “first line of defense” for quality and safety: the purity of intermediates, impurity control, and chiral selectivity directly determine the efficacy and safety of drugs ； It serves as the \"value hub\" of the industrial chain: it is connected to basic chemical raw materials on one end, and it supports the research and development as well as commercialization of innovative drugs on the other, covering the entire cycle from research and development to clinical use and production. Data shows that the market size for pharmaceutical intermediates in China has exceeded 260 billion yuan. In the global pipeline of innovative drugs, over 60% of new small-molecule drugs rely heavily on customized intermediate supplies. A strong intermediate ensures stability in the innovative drug industry chain ； If the intermediates are of high quality, the competitiveness of the innovative drug is strong. II. Core Value: How Intermediates Determine the Success or Failure of Innovative Drugs 1. R&D Accelerators: Turning \"impossible\" into \"possible\" The development of innovative drugs is a lengthy process with a high rate of failure, and intermediates play a key role in shortening this timeline and reducing risks. Provides derivative libraries and structural modules to rapidly verify structure-activity relationships, reducing the optimization time of lead compounds by 6–8 months ； Supports the rapid preparation of clinical batches to ensure a stable supply of samples for Phase I-III clinical trials ； Breaking through the challenges of complex molecular synthesis: multiple chiral centers, fused ring structures, and highly reactive functional groups all rely on intermediate-based approaches to overcome these difficulties. 2. Cost control: Making expensive drugs more accessible to the general public. In the process from research and development to market launch, process costs account for over 40%, and intermediates play a key role in reducing these costs. Advanced processes (enzymatic catalysis, continuous flow, asymmetric catalysis) can reduce production costs by 30%–50% ； Improve atom economy, reduce waste emissions, and make drugs more accessible ； The capacity for large-scale production directly determines whether new drugs can move from the laboratory to households across the country. 3. Supply chain security: Protecting the \"lifeline\" of innovative drugs. In the global pharmaceutical division of labor, intermediates are the links most prone to disruption. High-end intermediates have long relied on imports, facing issues such as high prices, long delivery times, and a high risk of supply disruptions ； With domestic substitution, not only is monopoly broken, but Chinese innovative drugs also gain a supply chain that is under their own control ； In popular fields such as anti-tumor, antiviral, GLP-1, and ADC therapies, domestic production of key intermediates has been achieved. III. Trends of the Times: The boom in innovative drugs brings a golden age for intermediates. Currently, China’s innovative drug industry is in its best phase of development ever, and the intermediates industry has also entered a period of rapid growth. Policy-driven: accelerated review of innovative drugs, implementation of the MAH system, and robust development of CDMOs have led to a surge in demand for high-end intermediates ； Technological upgrade: Moving from ordinary chemical products to chiral intermediates, high-purity intermediates, and customized intermediates, thereby increasing the added value significantly ； Global Shift: Leveraging advantages in cost, manufacturing capabilities, production capacity, and compliance, China has become the world’s largest supplier of pharmaceutical intermediates, serving the top 50 pharmaceutical companies globally ； Rapid growth in this sector: Cutting-edge therapies such as small-molecule targeted drugs, antibody-drug conjugates (ADCs), small nucleic acids, and CGT are driving annual demand for specialty intermediates to grow at a rate of over 18%. IV. Industrial Responsibility: Building a Strong Country in Intermediates to Become a Power in Innovative Drugs. Today’s intermediate industry in China has long shed the label of \"low-end contract manufacturing\" and is now moving toward technology leadership and global collaboration. The ee value of the chiral intermediate remains stable at over 99%, meeting international top-tier standards ； Technologies such as continuous flow, enzyme catalysis, and green synthesis are being implemented on a large industrial scale, leading to improved efficiency and reduced pollution ； A group of leading companies are deeply involved in global collaborations regarding original drugs, participating from the early stages of clinical development and ensuring supply throughout the entire lifecycle. A strong intermediate leads to strong innovative drugs ； A strong industry in innovative drugs means a strong pharmaceutical industry. It stands silently behind innovative drugs, supporting the backbone of pharmaceutical innovation in China with every precise molecule. Nanjing Kaitian Chemical has been active in the field of pharmaceutical intermediates for many years, focusing on the research, development, production, and supply of high-quality intermediates. With strict quality control, stable production capacity, and professional services, it helps accelerate the development of innovative drugs and promote industrial upgrading. It moves forward alongside China’s efforts in pharmaceutical innovation to build a healthier future for the country.